和誉-B今日盘中股价大幅上涨6.08%，引起了市场投资者的关注。
消息面上，此次股价波动主要与公司发布的积极年度业绩及核心产品的商业化进展有关。公司近日公布的截至2025年12月31日止年度业绩显示，集团收入达到6.12亿元人民币，同比增长21.45%，并连续第二年实现盈利。同时，其核心品种贝捷迈®（盐酸匹米替尼胶囊）的全球首个新药上市申请已在华获批，标志着公司正式进入商业化元年，市场对其未来增长空间和现金流改善抱有强烈预期。
分析指出，在贝捷迈®强劲的商业化预期推动下，公司有望步入“创新-变现 - 业绩验证”的新价值循环，为估值持续上行奠定基础，这共同提振了投资者信心，推动了股价在交易时段内的显著上扬。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.